Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy E DeZern

Showing results (1-10 of 199) with videos related to

Pageof 20
Sort By:
Hematology. American Society of Hematology. Education Program|December 6, 2015
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?Amy E DeZern
Hematology. American Society of Hematology. Education Program|December 10, 2021
Lower risk but high riskAmy E DeZern
Blood|April 4, 2024
A way to "mimic" the pathophysiology of acquired SAAAmy E DeZern
Blood|August 25, 2022
Playing with fire: unrecognized AA genetic predispositionAmy E DeZern
Blood|September 16, 2021
Relevant metrics: how significant CCUS truly isAmy E DeZern
Hematology. American Society of Hematology. Education Program|December 4, 2018
Treatments targeting MDS genetics: a fool's errand?Amy E DeZern
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2020
Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic SyndromesTania Jain, Amy E DeZern
Blood|November 14, 2024
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDSYasmin Abaza, Amy E DeZern
Best Practice & Research. Clinical Haematology|August 18, 2021
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndromeTheodoros Karantanos, Amy E DeZern
The Lancet. Haematology|December 8, 2023
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?Maximilian Stahl, Amy E DeZern
Pageof 20

Showing results (1-10 of 199) with videos related to

Sort By:
Pageof 20
Hematology. American Society of Hematology. Education Program|December 6, 2015
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?Amy E DeZern
Hematology. American Society of Hematology. Education Program|December 10, 2021
Lower risk but high riskAmy E DeZern
Blood|April 4, 2024
A way to "mimic" the pathophysiology of acquired SAAAmy E DeZern
Blood|August 25, 2022
Playing with fire: unrecognized AA genetic predispositionAmy E DeZern
Blood|September 16, 2021
Relevant metrics: how significant CCUS truly isAmy E DeZern
Hematology. American Society of Hematology. Education Program|December 4, 2018
Treatments targeting MDS genetics: a fool's errand?Amy E DeZern
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2020
Why Hurry Up and Wait? Transplantation in Lower-Risk Myelodysplastic SyndromesTania Jain, Amy E DeZern
Blood|November 14, 2024
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDSYasmin Abaza, Amy E DeZern
Best Practice & Research. Clinical Haematology|August 18, 2021
Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndromeTheodoros Karantanos, Amy E DeZern
The Lancet. Haematology|December 8, 2023
Is there a path forward for immunotherapy in patients with myelodysplastic syndromes?Maximilian Stahl, Amy E DeZern
Pageof 20